Street Calls of the Week
Natera, Inc. NASDAQ:NTRA Chief Financial Officer Michael Burkes Brophy sold 2,491 shares of common stock on September 30, 2025, at a price of $162.0528, totaling $403,673. The transaction comes as Natera demonstrates strong market performance, with the stock up 23% over the past year and the company maintaining a "GOOD" financial health rating according to InvestingPro analysis.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction decreased Brophy’s direct ownership in Natera. Following the transaction, Brophy directly owns 69,189 shares of the company. The $22.18 billion market cap company maintains strong liquidity with a current ratio of 3.72 and impressive revenue growth of 44.38% in the last twelve months.
On September 29, Brophy also exercised options on 6,250 shares of Natera common stock, which had a value of $0. These shares were related to the vesting of restricted stock units. For comprehensive insider trading analysis and additional financial metrics, access the detailed Pro Research Report available on InvestingPro.
In other recent news, Natera, Inc. has made significant strides in its clinical trials and product evaluations. The company has enrolled over 1,600 patients in its EXPAND trial, which is assessing the Fetal Focus single gene noninvasive prenatal test for inherited conditions. In the realm of oncology, Natera’s Signatera test has shown promising results, outperforming standard tumor markers in a large study involving testicular cancer patients. Additionally, the Signatera test has demonstrated strong results for monitoring recurrence and treatment response in early-stage uterine cancer patients.
Analyst activities have also been notable for Natera. Wells Fargo resumed coverage of the company with an Equal Weight rating, citing Natera’s robust position in the cell-free DNA testing market. Meanwhile, Piper Sandler reiterated an Overweight rating, highlighting the positive outcomes from Natera’s IMvigor011 trial, which showed a correlation between MRD-negative status and improved overall survival. These developments underscore Natera’s active engagement in advancing its testing technologies across various medical fields.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.